Trial Profile
A Phase 2, Multicenter, Randomized, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naive Adult Subjects With Genotype 1 Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; VX 135 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 04 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
- 13 Apr 2014 Interim results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.